Research Article

High viral SARS-CoV-2 load in placenta of patients with hypertensive disorders after COVID-19 during pregnancy

Fabre M^{a,b}, Calvo P^{b,c}, Ruiz-Martinez S^{b,c,d}, Peran M^{a,b}, Oros D^{b,c,d}, Medel Martinez A^e, Strunk M^{e,f}, Benito R^g, Schoorlemmer J^{b,h,i}, Paules C^{b,c,d}

a Instituto de Investigación Sanitario de Aragón (IIS Aragón) Biochemistry Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Spain

b Placental pathophysiology & fetal programming research group, B46_20R & GIIS-028 del IISA

c Instituto de Investigación Sanitario de Aragón (IIS Aragón), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Spain

d Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS. Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de la Investigación y Fondo Europeo de Desarrollo Regional (FEDER) Ref: RD16/0022/0013

e Laboratorio Satélite, Instituto Aragonés de Ciencias de la Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain

f Sequencing and Functional Genomics, Instituto Aragonés de Ciencias de la Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain

g Microbiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. Universidad de Zaragoza. IIS Aragón

h Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain

i ARAID Foundation, Zaragoza, Spain.

Short Title: SARS-CoV-2 viral load in placenta of patients with hypertensive disorders

Corresponding Author: Schoorlemmer J

Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain

Calle de San Juan Bosco, 13, 50009 Zaragoza, Spain

Tel.: +34 976 715 412; +34 672 022 215;

jonas@araid.es

Number of Tables: 2

Number of Figures: 4

Word count: 3686

Keywords: SARS-CoV-2, placenta, hypertensive disorders of pregnancy, COVID-19, placental viral load

1

2 **Abstract**

3 **Introduction:** Studies described an increased frequency of hypertensive disorders of
4 pregnancy after a COVID-19 episode. There is limited evidence about SARS-CoV-2 viral load in
5 placenta. This study aimed to investigate the relationship between SARS-CoV-2 viral load in
6 placenta and clinical development of HDP after COVID-19 throughout different periods of
7 gestation.

8 **Methods:** This was a case-control study in women with and without gestational hypertensive
9 disorders (HDP) after SARS-CoV-2 infection diagnosed by RT-PCR during pregnancy. Patients
10 were matched by gestational age at the moment of COVID-19 diagnosis. We performed an
11 analysis of SARS-CoV-2 RNA levels in placenta.

12 **Results:** A total of 28 women were enrolled. Sixteen patients were diagnosed with COVID-19
13 during the third trimester and the remaining twelve patients in the others trimesters. Ten
14 placentas (35.7%) were positive for SARS-CoV-2, nine of them (90%) belonged to the HDP
15 group versus one (10%) in control group ($p=0.009$). Those cases with the highest loads of viral
16 RNA developed severe-preeclampsia.

17 **Conclusion:** The presence of SARS-CoV-2 was more frequent in placentas of patients with HDP
18 after COVID-19. There seems to be a relationship between high viral load in the placenta and
19 the development of hypertensive disorders. We found SARS-CoV-2 viral load in placenta after
20 birth in mothers infected at the first half of pregnancy, but with negative nasopharyngeal RT-
21 PCR at delivery. Our data suggest that SARS-CoV-2 infection during pregnancy could trigger
22 gestational hypertensive disorders through placenta-related mechanisms.

23

24

25 INTRODUCTION

26 Several international studies have recently suggested an increase in preeclampsia and other
 27 hypertensive disorders of pregnancy (HDP) associated with SARS-CoV-2 infection during
 28 pregnancy [1,2,3,4] with classic signs and symptoms related to preeclampsia, such as
 29 hypertension, proteinuria, thrombocytopenia, elevated liver enzymes [5,6]. Preeclampsia (PE)
 30 is a pregnancy-specific multisystem disorder characterized by endothelial dysfunction that
 31 leads to the release of soluble factors into the maternal circulation responsible for the multi-
 32 organ injury [7]. These so-called preeclampsia-like syndromes are in some way clinical
 33 manifestations of maternal endothelial dysfunction.

34 The clinical manifestations of the SARS-CoV-2 infection support a key role for endothelial
 35 dysfunction in the pathobiology of this condition. SARS-CoV-2 infection induces an
 36 endotheliitis in different organs as a direct consequence of viral infection and the host
 37 inflammatory response [8,9]. Angiotensin-converting enzyme 2 (ACE2) is the major cellular-
 38 entry receptor for SARS-CoV-2 virus [10]. ACE2 is present prominently in the alveoli, but also in
 39 endothelial cells, which can be directly infected by the virus [11]. Besides, cytokine release
 40 syndrome can also drive endothelial damage independently [12]. Consequently, a distinctive
 41 feature of SARS-CoV-2 infection is vascular harm, with severe endothelial injury, widespread
 42 thrombosis and microangiopathy, in response to endothelial damage. Therefore, endothelial
 43 dysfunction seems to be the pathophysiological substrate for severe COVID-19 complications.

44 It is at present unknown how COVID-19 is associated with increased frequency of HDP (and
 45 especially PE) and whether similar mechanisms operate. COVID-19 associated PE-like disease
 46 may be an indirect result of maternal disease or more directly related to the presence of SARS-
 47 CoV-2 in the placenta. While initial studies had suggested that SARS-CoV-2 invades the
 48 placenta in some cases [13, 14, 15], posterior data suggest that is not very common [16, 17, 18,

19]. Consistent with a low frequency presence of SARS-CoV-2 in the placenta [22], vertical transmission is rather infrequent [21]: a systematic review reported a rate of 3.2% vertical transmission in mothers who tested positive for SARS-CoV-2 (diagnosed by RT-PCR) during the third trimester of pregnancy [22]. A recent study of placentas taken from COVID-19 positive mothers [23] describes a low-level presence of RNA in about half of placentas. No substantial histopathological, maternal, or neonatal outcome features were detected associated with this low level of viral RNA. However, a high SARS-CoV-2 RNA level was detected in only one patient, who exhibited severe placental injury in the form of extensive fibrin deposition, necrosis of the syncytiotrophoblast layer of the villi and apoptosis. This observation fits the hypothesis that only limited placental pathology is associated with COVID-19, except for cases with very high SARS CoV2 RNA levels, the latter indicative of high viral load.

60

Considering the increase in hypertensive disorders in COVID-19 patients, this study aimed to investigate the relationship between SARS-CoV-2 viral load in placental tissue at birth and the development of preeclampsia or gestational hypertension after COVID-19 throughout different periods of gestation. The clinical history of three cases of preeclampsia, with positive placental PCR tests for SARS-CoV-2 during each of the three semesters of pregnancy, is described in detail as an example.

67

68 **Materials and Methods**

We conducted a case-control study in women diagnosed with COVID-19 during pregnancy with and without gestational hypertensive disorders. We perform an analysis of SARS-CoV-2 RNA levels in placental tissue and SARS-CoV-2 antibodies in umbilical cord. Patients were recruited at the moment of delivery between May 2020 and February 2021 at a tertiary University

Center. Cases were defined as women who tested positive for SARS-CoV-2 during pregnancy and were diagnosed with gestational hypertensive disorders. Controls, defined as SARS-CoV-2 positive women without HDP during pregnancy, were paired by gestational age at the moment of SARS-CoV-2 diagnosis.

SARS-CoV-2 infection was diagnosed based on positive RT-PCR test for SARS-CoV-2 from nasopharyngeal swabs. RT-PCR test kits from different companies were used: Viasure (CerTest Biotec, Zaragoza, Spain), M2000 SARS-CoV-2 Assay (Abbott RealTime SARS-CoV-2 Assay, Abbott Molecular, Abbott Park, IL, USA), TaqPath COVID-19 (Thermo Fisher Scientific, USA-FDA) and Alinity SARS-CoV-2 (Abbott Alinity, Abbott Molecular, Abbott Park, IL, USA). Information on these test kits are listed in Supplementary Table1. As suggested by the manufacturer for nasopharyngeal specimens, cycle threshold (CT) values below 37 were taken as positive. Besides, all women who were hospitalized for delivery were screened for SARS-CoV-2 infection using RT-PCR on nasopharyngeal swabs shortly before giving birth. However, in the case of pregnant women who had already overcome the infection, PCR-RT was only performed around delivery if the latest negative PCR test was more than 3 months ago. As a result, four patients (3, 4, 15 and 16) were not tested for SARS-CoV-2 infection at the time of delivery. Prophylactic treatment with low molecular weight heparin for 14 days was applied to COVID-19 women diagnosed by RT-PCR [24]. COVID-19 has been divided into three types [25]: asymptomatic infection refers no clinical symptoms or signs; mild infection refers symptoms such as fever, cough, headache, anosmia and asthenia; and severe infection refers dyspnea, hypoxemia accompanied by chest imaging compatible with pneumonia and respiratory infection.

Placental tissue samples were taken at the moment of delivery, taking villous tissue while carefully trying to avoid the overlying maternal tissue. Placental samples, approximately 1 cm³ in size, were placed into tubes containing 1 ml of preservative solution (RNA^{later} Fisher Scientific) at 4°C. After 24h, excess RNA^{later} was removed, and the samples were stored at -80°C. Tissue was homogenized, RNA was extracted, treated with DNase I, repurified and resuspended as previously described [26]. Concentrations were measured using Nanodrop, 100 ng of RNA was used in downstream PCR analysis. RT-PCR for SARS-CoV-2 in placenta tissue samples was performed using the TaqPath COVID-19 CE-IVD RT-PCR kit (Catalog Number A48067; Life Technologies Europe, Bleiswijk, The Netherlands) on a QuantStudio5 (Applied Biosystems; ThermoFisher Scientific) apparatus. The limit of detection of this kit is listed as 10 GCEs (Genomic Copy Equivalents). As this assay targets N, ORF1ab and S genes, only samples with three positive targets were considered as SARS-CoV-2 positive. SARS-CoV-2 tissue load in placenta is referred to in the manuscript as viral load and is expressed as CT values of RT-PCR.

We collected umbilical cord plasma in EDTA and samples were centrifuged. Serological assays were determined on the same day by chemiluminescent microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG. The SARS-CoV-2 IgG assay is designed to detect IgG antibodies to the nucleocapsid protein of SARS-CoV-2. (IgG; SARS-CoV-2 IgG Assay, Abbott Laboratories Ireland, Dublin, Ireland) and IgM+IgA antibodies (IgM+IgA; COVID-19 VIRCLIA IgM+IgA, Vircell Microbiologists, Granada, Spain).

Gestational hypertensive disorders were divided into four categories, defined according to the criteria proposed by American college of Obstetrics and Gynaecologists [27]: preeclampsia, chronic hypertension, chronic hypertension with superimposed preeclampsia and gestational hypertension. First trimester risk of early-onset preeclampsia was retrospectively calculated according to maternal characteristics, obstetric history, maternal blood pressure, maternal

serum pregnancy-associated plasma protein-A and uterine artery pulsatility index, using SsdwLab6 version 6.1 package (SBP Soft 2007 S.L.) [28].

Clinical characteristics, laboratory results, maternal and neonatal outcomes were collected from medical records. All patients provided written informed consent. The study was approved by the Research Ethics Committee of the Community of Aragon (C.I. PI21/155 and COL21/000) and all patients provided written informed consent.

Statistical analysis was performed using SPSS 22.0. Categorical variables were presented as frequencies or percentages. Continuous variables were presented using mean $\pm$ standard deviation, median, or range. For continuous variables, Shapiro Wilk tests of normality were used to evaluate the distributions. Data were analysed using Student t test or Mann–Whitney U test. Statistical significance was considered $p < 0.05$.

Results

Fourteen women in the case group (COVID-19 positive and diagnosis of HDP) and fourteen women in the control group, matched for gestational age at the time of COVID-19 diagnosis, were included. Out of those 14 cases, 9 cases (64.3%) had preeclampsia and five cases (35.7%) had gestational hypertension. Demographic and clinical data, as well as perinatal and neonatal outcomes are shown in table 1. There were no significant differences in maternal age, maternal weight, risk of preeclampsia at 1st trimester, nulliparity rate and diabetes mellitus between the two groups. The vast majority of patients, eight pairs, represent pregnant women who were diagnosed with COVID-19 during the third trimester, whereas five pairs in the second trimester and only one pair in the first trimester. Mean gestational age at delivery was 268.1 days in the case group and 278.9 days in the control group ($p=0.005$). Women with HPD also exhibited lower birthweight compared with the control group (2852.5g SD 467.0 versus

144 3282.9g SD: 435.9; $p=0.005$). There were no significant differences for small for gestational
145 age, umbilical arterial $pH < 7.1$. Induced labor and cesarean was significantly more frequent in
146 the HDP group compared to controls ($p=0.003$ and $p=0.015$, respectively).

147 The chronology of diagnosis of HDP and SARS-CoV-2 infection of each patient is summarized in
148 table 2. There was no significant difference in the severity of SARS-CoV-2 symptoms initial
149 between the groups ($p=0.341$). Thirteen had no symptoms, thirteen patients had mild and
150 only two patients had severe SARS-CoV-2 infection (Table 2). No patient required admission to
151 the intensive care unit.

152 Using a sensitive RT-PCR assay, ten placentas (35.7%) from SARS-CoV-2 positive women during
153 pregnancy, tested positive for SARS-CoV-2 RNA at birth. In the case group, we found nine
154 positive placentas (9/10, 90%) while in control group only one placenta (1/10, 10%) were
155 positive ($p=0.009$) (shown in Fig.1). Moreover, 7 of nine 9 placentas (77.8%) belong to women
156 diagnosed with preeclampsia. Focusing on positive placentas, we have three cases with high
157 loads of viral RNA ($CTs \leq 28$) (see below), and the remaining seven cases with low loads of viral
158 RNA (median CT of 30.6; Interquartile range 28.7-33.9) (Table 2).

159 While only six pairs of pregnancies with positive SARS-CoV-2 tests during the first or second
160 trimester ($GA \leq 27$ weeks) were analyzed (Table 2), several remarkable results deserve
161 mentioning. First, out of the six cases with HDP, six out of six had positive placental SARS-CoV-
162 2 test at birth. In contrast, among the corresponding six control cases without HDP, only one
163 tested positive for placental SARS-CoV-2 (Table 2). It is possible therefore, that the continued
164 presence of SARS-CoV-2 in the placenta promotes HDP or vice versa. Moreover, out of ten
165 pregnancies for which data are available with these early SARS-CoV-2 infections, only one
166 mother remained positive at delivery ($N=6$), while seven placentas tested positive. This latter

167 data suggests that infection with SARS-CoV-2 during early pregnancy may commonly result in
168 persisting placental presence of SARS-CoV-2.

169 Finally, antibody quantification was performed for 87.5% neonates with umbilical cord blood
170 samples. Thirteen infants tested positive for IgG on the first 10 days of life, and none tested
171 positive for IgM+IgA. There was no significant difference between the groups in the number of
172 neonates that tested positive for SARS-CoV-2 IgG ($p=0.688$).

173 Among the placentas that tested positive, three cases with high loads of viral RNA (Cts = 15;
174 23; 28, respectively) represented cases of severe preeclampsia (Table 2). Case number 1
175 (shown in Fig.2) was a woman with no medical history of interest. The estimated risk of early-
176 onset preeclampsia in the first trimester was 1/122. She presented positive SARS-CoV-2 RT-
177 PCR (CT: 18.7) at week 8 of gestation and infection courses asymptomatic. Two weeks later,
178 she tested negative for SARS-CoV-2 by RT-PCR. At 35 week of gestation, she debuted with
179 severe preeclampsia, which required admission to the hospital and treatment with intravenous
180 labetalol and magnesium sulfate. RT-PCR for SARS-CoV-2 infection was performed at the time
181 of admission, with a negative result. Termination of pregnancy was in week 35 + 2 for this
182 reason. A female of 1875 grams, APGAR test was 9 and 10 at 1 and 5 minutes, respectively,
183 and pH 7.31 without antibodies against SARS-CoV-2 was born. Placental analysis for SARS-CoV-
184 2 was positive, with a high viral load by RT-PCR.

185 Case number 11 (shown in Fig.3) was a nulliparous woman with a spontaneous monochorionic
186 diamniotic twin. The estimated risk of early-onset preeclampsia in the first trimester was 1/15.
187 Pregnancy of normal course until week 26+5, when she debuted with fever, cough and
188 myalgias. RT-PCR results for SARS-CoV-2 was positive (CT: 5.9). At 34+0 she tested negative for
189 SARS-CoV-2 by RT-PCR. In week 35, the patient presented non-severe preeclampsia, well
190 controlled with oral treatment with alfamethyldopa. At 36+5 weeks was decided an elective

191 delivery due to the onset of severe preeclampsia, ending in an intrapartum caesarean section.
192 The first male twin was born: 3320 grams, APGAR test was 9 and 10 at 1 and 5 minutes,
193 respectively, and was admitted for observation for 2 days. Second twin, male, 2360 grams,
194 with APGAR test of 4 and 8 at 1 and 5 minutes, and he was admitted for observation for 6
195 days. Cord blood serology was positive for IgG and negative for IgM. The placenta was clearly
196 positive for SARS-CoV 19 by RT-PCR.

197 Case 23 (shown in Fig.4) was a woman with a bi-chorionic biamniotic twin pregnancy. The
198 estimated risk of early-onset preeclampsia in the first trimester was 1/4440. Gestation of
199 normal course until onset of fever, cough and malaise, with positive result in RT-PCR SARS-
200 CoV-2 (CT: 20.2) at 38 +3 weeks of gestation. The patient presented blood pressure around
201 150/90 mmHg, with positive creatinine protein ratio and a pneumonia on chest X-ray that
202 required treatment with low molecular weight heparin, steroids and oxygen therapy.
203 Laboratory tests were performed in week 38+4, HELLP syndrome was detected (59000 mm³
204 platelets, LDH 443 U/L and GOT 43 U/L), and it was decided to elective delivery at that time by
205 caesarean section due to HELLP and breech presentation. The birthweight of the first male
206 twin was 2820 grams, with APGAR test 6 and 8 at 1 and 5 minutes, respectively. The
207 birthweight of the second male twin was 2840 grams, APGAR test was 2 and 8 at 1 and 5
208 minutes. Both were admitted to the neonatal unit and the mother had no contact with the
209 newborns after the cesarean section. RT-PCR SARS-CoV-2 was performed on both, positive at
210 3 and 2 days of life respectively, as well as SARS-CoV-2 serologies, which were positive at 19
211 and 16 days of life respectively. The analysis of placenta yielded a clear positive result for
212 SARS-CoV-2 (CT 23.1) [6].

213

214 Discussion/Conclusion

215 Previous viral epidemics have confirmed that pregnant women are at increased risk for severe
216 virus infection [30, 31, 32]. SARS-CoV-2 is not an exception, as pregnant patients with COVID-
217 19 are at increased risk for severe illness [33, 34] and adverse pregnancy outcomes [8].
218 Therefore, women with COVID-19 may require closer control than non-infected pregnant
219 population.

220 Placental histopathology at term in women suffering COVID-19 has been examined in relation
221 to disease symptoms such as systemic inflammatory responses, hypercoagulation and
222 intervillous thrombi [35, 36]. The presence of SARS-CoV-2 in the placenta has been studied in
223 the context of horizontal transmission of the virus [22] with an early study reporting 7.7%
224 positivity (2/26). However, only a very limited number of studies report data that allow a direct
225 comparison between the placental presence of SARS-CoV-2 and HDP. An early prospective
226 cohort study [16] describes the inability to detect SARS-CoV-2 in placenta by RNA in situ
227 hybridization in 44 women with SARS-CoV-2 diagnosis in the third trimester. Afterwards, since
228 the first report describing the detection of SARS-CoV-2 fetal membrane samples [37], similar
229 reports have followed. Hosier et al [38] mentions high viral load in the placenta (CT<16) of a
230 single woman with severe preeclampsia and SARS-CoV-2 infection during the late second
231 trimester of pregnancy. In a posterior study, a rate of 47% SARS-CoV-2 positive placenta tissue
232 was reported in 21 women who were diagnosed (using RT-PCR) between 35 and 40 weeks of
233 gestation [23]. In this latter study, a woman who exhibited severe placental damage delivered
234 a baby with neurological manifestations. Based on these combined two cases, the possibility
235 was raised that the severity of SARS-CoV-2-mediated placental pathology might be directly
236 related to placental SARS-CoV-2 viral load.

237 Following up on these studies, we further assessed the relationship between the SARS-CoV-2
238 viral load in placental tissue and the development of HDP in 14 HDP cases and paired controls,

all diagnosed with COVID-19. Out of 28 samples tested in our study, we identified 10 placental tissue samples that tested positive for SARS-CoV-2 (35.7% of total), nine of them belonging to the hypertension disorders during pregnancy (HDP) group. We observed that, among patients with SARS-CoV-2 infection during gestation, the frequency of a positive placental SARS-CoV-2 PCR test was much higher in the HDP group compared to the non-HDP group. Furthermore, we detected that the percentage of cases with a positive placental SARS-CoV-2 RT-PCR test trend differently between PE and AHT ($p= 0.065$). In fact, the three most severe cases of preeclampsia (cases N° 1, 11 and 23), showed higher placental viral load than all the others. Moreover, each of the three tested positive for SARS-CoV-2 in a different trimester of gestation. It has been argued that localization of SARS-CoV-2 to fetal cells such as the syncytiotrophoblast as opposed to maternal uterine cells requires detection by immunohistochemistry or RNA in situ hybridization [16]. We only applied RT-PCR and can therefore not exclude that the placenta samples we have analyzed do contain maternal tissue. Considering that maternal tissue was avoided when taking samples, and for the sake of simplicity, we interpret positive placental RT-PCR results as representative of viral load in villous placenta. This might indicate that in women susceptible to HDP, the presence of placental SARS-CoV-2 may contribute to the severity of the disorder. We suggest that a relationship between a higher viral load in placenta tissue and the severity of the hypertensive disorder deserves consideration.

Placental characteristics described in SARS-CoV-2 infection include maternal vascular perfusion and inflammation [35, 39]. It has been postulated that the detrimental health outcomes associated with HDP are the result of generalized endothelial and vascular dysfunction [40]. Similarly, a consequence of SARS-CoV-2 infection is endothelial injury in different organs resulting directly or indirectly from the host inflammatory response [9]. Alternatively [41], it has been proposed that direct infection of syncytiotrophoblast cells in the placenta by SARS-

264 CoV-2 may cause placental dysfunction and pregnancy complications [42]. The
265 pathophysiological mechanisms that connect placental SARS-CoV-2 with HDP remain to be
266 established.

267 The main limitation of our study is the small sample size. Further studies with a large number
268 of patients are required to confirm the association between high SARS-CoV-2 viral load in
269 placenta tissue and the development of HDP. Moreover, our hospital's protocols changed as
270 the pandemic progressed. Therefore, different methodologies have been used for viral RNA
271 detection. As not all tests proved to be equally sensitive and specific, the use of distinct tests
272 may have caused a discrepancy with studies published previously [13, 16, 22]. In addition, we
273 do not have sequencing data from nasopharyngeal maternal swabs available, but all pregnant
274 women were diagnosed before the alpha (B.1.1.7 UK) variant and delta (B.1.617.2 India) were
275 routinely detected in our area. A final limitation to address is the fact that for each placenta
276 we tested only a single sample. As SARS-CoV2 is not necessarily homogenously present (or
277 absent) throughout the placenta, the identification of samples as positive or negative should
278 be interpreted in this context.

279 Among the strengths of the study, we highlight the inclusion of women who tested positive for
280 SARS-CoV-2 in each of the three trimesters of pregnancy. We demonstrate a higher viral load
281 in placental tissue in the case group than in the control group and a higher frequency of
282 infected placentas. Besides, as SARS-CoV-2 RT-PCR test carried out at the time of birth showed
283 all mothers tested negative, we could rule out the possibility of acute maternal infection
284 during delivery. Some cases we describe with high placenta SARS-CoV-2 levels, specifically
285 patient 1 and patient 11, had negative RT-PCR results at the time of delivery. This data shows
286 that placenta infection may persist in the absence of maternal infection. In the limited of cases
287 we describe, this persistent viral presence is associated with the development of adverse
288 perinatal outcomes.

289

290 In summary, this study assess the relationship between SARS-CoV-2 viral load in placental
291 tissue and the maternal risk of developing gestational hypertensive disorders. We find that the
292 presence of SARS-CoV-2 (although we do not formally prove viral infection) was more frequent
293 placentas of the HDP group compared to placentas of COVID-19 mothers without HDP. We
294 detect placental RNA representative of SARS-CoV-2 infection at high levels in a limited number
295 of PE cases, and at lower levels in about 25% of placentas from COVID-19 positive mothers.
296 There are different ways in which the infant of a PCR positive mother could be affected by
297 SARS-CoV2: maternal inflammation and endothelial damage may be transmitted to the
298 placenta in the form of cytokines which might modulate the fetal immune system [43].
299 Alternatively, SARS-CoV-2 infection of the placenta may directly influence the fetal
300 environment. The presence of placental viral RNA needs to be investigated in a much larger
301 cohort to clarify if and in what frequency if SARS-CoV-2 infection during pregnancy does trigger
302 gestational hypertensive disorders through placenta-related mechanisms. Our work
303 contributes to the understanding of how SARS-CoV-2 virus affects pregnancy, which includes
304 the possibility that placental infection contributes to pregnancy complications. Better and
305 more detailed understanding of the placental disease process may aid or could be essential for
306 appropriate monitoring during pregnancy and providing appropriate postnatal care.

References [Numerical]

1. Papageorgiou AT, Deruelle P, Gunier RB, et al. Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study [published online ahead of print, 2021 Jun 26]. *Am J Obstet Gynecol*. 2021;S0002-9378(21)00561-5. doi:10.1016/j.ajog.2021.05.014
2. Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. *JAMA Pediatr*. Published online April 22, 2021. doi:10.1001/jamapediatrics.2021.1050
3. Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM*. 2020;2(2):100107. doi:10.1016/j.ajogmf.2020.100107
4. Ahlberg M, Neovius M, Saltvedt S, et al. Association of SARS-CoV-2 test status and pregnancy Outcomes. *JAMA*. 2020;324(17):1782-1785. doi:10.1001/jama.2020.19124
5. Mendoza M, Garcia-Ruiz I, Maiz N, et al. Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study. *BJOG*. 2020;127(11):1374-1380. doi:10.1111/1471-0528.16339
6. Abadía-Cuchí N, Ruiz-Martínez S, Fabre M, et al. SARS-CoV-2 congenital infection and pre-eclampsia-like syndrome in dichorionic twins: A case report and review of the literature. *Int J Gynaecol Obstet*. 2021;154(2):370-372. doi:10.1002/ijgo.13749
7. Romero R, Chaiworapongsa T. Preeclampsia: a link between trophoblast dysregulation and an antiangiogenic state. *J Clin Invest*. 2013; 123:2775–2777. doi: 10.1172/JCI70431
8. Huertas A, Montani D, Savale L, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. *Eur Respir J*. 2020;56(1):2001634. Published 2020 Jul 30. doi:10.1183/13993003.01634-2020
9. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5
10. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579(7798):270–3.
11. Kumar A, Narayan RK, Kumari C, et al. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients. *Med Hypotheses*. 2020;145:110320. doi:10.1016/j.mehy.2020.110320
12. Castro, P., Palomo, M., Moreno-Castaño, A.B. et al. Is the endothelium the missing link in the pathophysiology and treatment of COVID-19 complications?. *Cardiovasc Drugs Ther* (2021). <https://doi.org/10.1007/s10557-021-07207-w>
13. Schwartz DA, Morotti D, Beigi B, Moshfegh F, Zafaranloo N, Patanè L. Confirming vertical fetal infection with coronavirus disease 2019: neonatal and pathology criteria for early onset and transplacental transmission of severe acute respiratory syndrome coronavirus 2 from infected pregnant mothers. *Arch Pathol Lab Med*. 2020 Dec 1;144(12):1451-1456. doi: 10.5858/arpa.2020-0442-SA.
14. Patanè L, Morotti D, Giunta MR, Sigismondi C, Piccoli MG, Frigerio L, et al. Vertical transmission of coronavirus disease 2019: severe acute respiratory syndrome coronavirus 2 RNA on the fetal side of the placenta in pregnancies with coronavirus disease 2019–positive mothers and neonates at birth. *Am J Obstet Gynecol MFM*. 2020 Aug;2(3):100145.
15. Kirtsman M, Diambomba Y, Poutanen SM, Malinowski AK, Vlachodimitropoulou E, Parks WT, et al. Probable congenital sars-cov-2 infection in a neonate born to a woman with active sars-cov-2 infection. *Cmaj*. 2020;192(24):E647–50.
16. Edlow AG, Li JZ, Collier AY, et al. Assessment of maternal and neonatal SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 Pandemic. *JAMA Netw Open*. 2020;3(12):e2030455. Published 2020 Dec 1. doi:10.1001/jamanetworkopen.2020.30455

17. Smithgall MC, Liu-Jarin X, Hamele-Bena D, Cimic A, Mourad M, Debelenko L, Chen X. Third-trimester placentas of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive women: histomorphology, including viral immunohistochemistry and in-situ hybridization. *Histopathology*. 2020 Dec;77(6):994-999. doi: 10.1111/his.14215. Epub 2020 Sep 26. PMID: 32692408; PMCID: PMC7405484.
18. Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. *Ann Diagn Pathol*. 2020;46:151530. doi:10.1016/j.anndiagpath.2020.151530
19. Raschetti R, Vivanti AJ, Vauloup-Fellous C, et al. Synthesis and systematic review of reported neonatal SARS-CoV-2 infections. *Nat Commun*. 2020;11(1): 5164. doi:10.1038/s41467-020-18982-9
20. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 in pregnant women: a report based on 116 cases. *Am J Obstet Gynecol*. 2020;223(1):111.e1-111.e14. doi:10.1016/j.ajog.2020.04.014
21. Bwire GM, Njiro BJ, Mwakawanga DL, Sabas D, Sunguya BF. Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: A living systematic review. *J Med Virol*. 2021 Mar;93(3):1361-1369. doi: 10.1002/jmv.26622. Epub 2020 Nov 10. PMID: 33090535.
22. Kotlyar AM, Grechukhina O, Chen A, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2021;224(1):35-53.e3. doi:10.1016/j.ajog.2020.07.049
23. Cribiù FM, Erra R, Pagni L, et al. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. *J Clin Invest*. 2021;131(6):e145427. doi:10.1172/JCI145427
24. Lou-Mercadé AC, Gavín O, Oros D, et al. Prevention of thrombosis in pregnant women with suspected SARS-CoV-2 infection: clinical management algorithm. *Ultrasound Obstet Gynecol*. 2020;56(1):111-112. doi:10.1002/uog.22096
25. Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. *J Microbiol Immunol Infect*. 2021;54(1):12-16. doi:10.1016/j.jmii.2020.05.001
26. Oros D, Strunk M, Breton P, et al. Altered gene expression in human placenta after suspected preterm labour. *Placenta*. 2017;55:21-28. doi:10.1016/j.placenta.2017.04.025.
27. Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. *Hypertension*. 2018;72(1):24-43. doi:10.1161/HYPERTENSIONAHA.117.10803
28. Serra B, Mendoza M, Scazzocchio E, Meler E, Nolla M, Sabrià E, Rodríguez I, Carreras E. A new model for screening for early-onset preeclampsia. *Am J Obstet Gynecol*. 2020 Jun;222(6):608.e1-608.e18. doi: 10.1016/j.ajog.2020.01.020. Epub 2020 Jan 21. PMID: 31972161.
29. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. *Am J Reprod Immunol*. 2015;73(3):199-213. doi:10.1111/aji.12355
30. Meijer WJ, van Noortwijk AG, Bruinse HW, Wensing AM. Influenza virus infection in pregnancy: a review. *Acta Obstet Gynecol Scand*. 2015 Aug;94(8):797-819. doi: 10.1111/aogs.12680. Epub 2015 Jun 13. PMID: 26012384.
31. Olgun NS. Viral infections in pregnancy: A Focus on Ebola Virus. *Curr Pharm Des*. 2018;24(9):993-998. doi: 10.2174/1381612824666180130121946. PMID: 29384053; PMCID: PMC6419752.
32. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* 2020;370:m3320-m3320.
33. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy Status - United States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(44):1641-1647. Published 2020 Nov 6. doi:10.15585/mmwr.mm6944e3

34. Patberg ET, Adams T, Rekawek P, et al. Coronavirus disease 2019 infection and placental histopathology in women delivering at term [published correction appears in Am J Obstet Gynecol. 2021 Jun 10;]. Am J Obstet Gynecol. 2021;224(4):382.e1-382.e18. doi:10.1016/j.ajog.2020.10.020
35. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental pathology in COVID-19. Preprint. medRxiv. 2020;2020.05.08.20093229. Published 2020 May 12. doi:10.1101/2020.05.08.20093229
36. Prabhu M, Cagino K, Matthews KC, et al. Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG. 2020;127(12):1548-1556. doi:10.1111/1471-0528.16403
37. Penfield CA, Brubaker SG, Limaye MA, et al. Detection of severe acute respiratory syndrome coronavirus 2 in placental and fetal membrane samples. Am J Obstet Gynecol MFM. 2020;2(3):100133. doi:10.1016/j.ajogmf.2020.100133
38. Hosier H, Farhadian SF, Morotti RA, et al. SARS-CoV-2 infection of the placenta. J Clin Invest. 2020;130(9):4947-4953. doi:10.1172/JCI139569
39. Lu-Culligan A, Chavan AR, Vijayakumar P, et al. SARS-CoV-2 infection in pregnancy is associated with robust inflammatory response at the maternal-fetal interface. Preprint. medRxiv. 2021;2021.01.25.21250452. Published 2021 Jan 26. doi:10.1101/2021.01.25.21250452
40. Brennan LJ, Morton JS, Davidge ST. Vascular dysfunction in preeclampsia. Microcirculation. 2014 Jan;21(1):4-14. doi: 10.1111/micc.12079. PMID: 23890192.
41. Levy A, Yagil Y, Bursztyn M, Barkalifa R, Scharf S, Yagil C. ACE2 expression and activity are enhanced during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R1953-61. doi: 10.1152/ajpregu.90592.2008. Epub 2008 Oct 22.
42. Li M, Chen L, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study. PLoS One. 2020;15(4):e0230295. Published 2020 Apr 16. doi:10.1371/journal.pone.0230295
43. Matute J, Finander B, Pepin D, et al. Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestation. Preprint. Res Sq. 2021;rs.3.rs-311000. Published 2021 Mar 16. doi:10.21203/rs.3.rs-311000/v1

Figure Legends

Figure 1. % RT-PCR positive placenta: cases group vs control group. Ten placentas ($35.7\% = 3.57\% + 32.14\%$) tested positive for SARS-CoV-2 RNA. Nine positive placentas in the cases group (9/28, 32.14%) while in control group only one placenta were positive (1/28, 3.57%). Seven (7/28, 25%) belong to women diagnosed with preeclampsia vs two of nine belong to women diagnosed with gestational hypertension (2/28, 7.14%).

Figure 2. Timeline of case 1. TPAL: term, pre-term, abortion, life; LMWH: low molecular weight heparin; PAPP-A: pregnancy-associated plasma protein-A; MoM: multiple of median; BP: Mean Arterial Blood Pressure; UtA PI: uterine artery resistance pulsatility index; w: weeks; EFW: estimated fetal weight; PI UA: umbilical artery pulsatility index; PI MCA: fetal middle cerebral artery pulsatility index; IUGR: Intrauterine growth restriction; BP: blood pressure.

Figure 3. Timeline of case 11. TPAL: term, pre-term, abortion, life; LMWH: low molecular weight heparin; PAPP-A: pregnancy-associated plasma protein-A; MoM: multiple of median; BP: Mean Arterial Blood Pressure; UtA PI: uterine artery resistance pulsatility index; w: weeks; EFW: estimated fetal weight; PI UA: umbilical artery pulsatility index; PI MCA: fetal middle cerebral artery pulsatility index; IUGR: Intrauterine growth restriction; BP: blood pressure; NA: neonatal admission.

Figure 4. Timeline of case 23. TPAL: term, pre-term, abortion, life; LMWH: low molecular weight heparin; PAPP-A: pregnancy-associated plasma protein-A; MoM: multiple of median; BP: Mean Arterial Blood Pressure; UtA PI: uterine artery resistance pulsatility index; w: weeks; EFW: estimated fetal weight; PI UA: umbilical artery pulsatility index; PI MCA: fetal middle cerebral artery pulsatility index; IUGR: Intrauterine growth restriction; BP: blood pressure; NA: neonatal admission.

	CASE GROUP (n=14)	CONTROL GROUP (n=14)	p
Demographic maternal data			
Maternal age (SD), years	31.93 (6.6)	30.36 (5.8)	0.506
Maternal weight (SD), kg	69.32 (10.5)	68.57 (13.2)	0.868
Caucasian (%)	9 (64.3)	4 (28.6)	0.063
1 ^o trimester high risk for Preeclampsia (%)	5 (35.7)	3 (21.4)	0.194
Diabetes mellitus (%)	0 (0)	1 (7.14)	0.317
Nullipara (%)	4 (28.6)	7 (50)	0.317
Maternal and neonatal outcome at delivery			
Gestational age at birth mean (SD), days	268.1 (10.8)	278.9 (7.8)	0.005
Birth weight, mean (SD), kg	2852.5 (467.0)	3282.9 (435.9)	0.018
SGA (<10th centile) (%)	4 (28.6)	1 (7.2)	0.146
Induced labor (%)	12 (85.1)	4 (28.6)	0.003
Cesarean delivery (%)	5 (35.7)	0 (0)	0.015
pH<7.1 (%)	2 (14.3)	0(0)	0.541
Preterm birth (<37 wk gestation) (%)	3 (21.4)	0(0)	0.072
Description of SARS-CoV-2			
Trimester of SARS-CoV-2 infection			
1 ^o (%)	1 (7.2)	1 (7.2)	1
2 ^o (%)	5 (35.7)	5 (35.7)	
3 ^o (%)	8 (57.1)	8 (57.1)	
COVID-19 Symptoms			
No	6 (42.9)	7(50)	0.341
Mild	6 (42.9)	7 (50)	
Severe	2 (14.2)	0 (0)	
Interval from diagnosis of SARS-CoV-2 to delivery (SD), d	61.86 (54.79)	72.64 (57.7)	0.616
Positive SARS-CoV-2 RT-PCR Placenta tissue (CT<37) (%)	9 (64.3)	1 (7.2)	0.009
Neonatal IgG (%)*	6 (42.9)	7 (50)	0.688
Table 1. SD: standard deviation; CT: cycle threshold value RT-PCR; SGA: small for gestational age *Analyzed 24 of 28.			

Table 1. Demographic data and obstetrical and SARS-CoV-2 infection characteristics

		DIAGNOSIS SARS-COV-2		DIAGNOSIS HDP			DELIVERY						NEONATAL ANTIBODIES SARS-CoV-2	
	Nº	SYN	GA	HDP	GA	Interval DEL-HDP (Days)	GA	Interval DEL - SARS (Days)	RT-PCR Result nasopharyngeal*	RT-PCR Result placenta tissue	CT RT-PCR Placenta tissue	Copy number/μl	IgG	IgM+IgA
CASE	1	No	8+0	S-PE	35+0	185	35+2	187	Negative	Positive	28.7	1158.3	Negative	N/A
CONTROL	2	Mild	9+3				38+5	202	Negative	Negative	≥40	0	Negative	N/A
CASE	3	No	21+3	S-PE	36+3	105	36+5	107	N/A	Positive	33.5	41.9	Negative	Negative
CONTROL	4	Mild	20+4				39+5	133	N/A	Negative	≥40	0	Positive	Negative
CASE	5	Mild	24+4	GHT	37+1	88	39+5	106	Negative	Positive	32.4	91.8	Positive	Negative
CONTROL	6	Mild	23+4				40+2	117	Positive	Negative	≥40	0	Positive	Negative
CASE	7	Mild	24+6	PE	36+4	82	37+1	86	Negative	Positive	31.7	150.5	Positive	Negative
CONTROL	8	Mild	25+1				39+2	99	Negative	Positive	33.9	32.1	Positive	Negative
CASE	9	Mild	25+6	GHT	38+0	85	40+1	99	Negative	Positive	33.1	57.4	Positive	Negative
CONTROL	10	Mild	25+5				41+2	109	Negative	Negative	≥40	0	Positive	Negative
CASE	11	Mild	26+6	S-PE	35+0	57	36+5	71	Negative	Positive	23.1	56377.8	Positive	Negative
CONTROL	12	Mild	27+4				40+2	89	Negative	Negative	≥40	0	Positive	Negative
CASE	13	Mild	29+4	GHT	35+3	42	39+6	73	Negative	Negative	≥40	0	N/A	N/A
CONTROL	14	No	30+0				39+1	64	Negative	Negative	≥40	0	N/A	N/A
CASE	15	Severe	30+0	PE	33+3	25	37+2	52	N/A	Negative	≥40	0	Positive	Negative
CONTROL	16	No	29+4				41+0	80	N/A	Negative	≥40	0	Positive	Negative
CASE	17	No	31+0	GHT	36+5	63	40+4	67	Negative	Negative	≥40	0	N	N/A
CONTROL	18	No	31+2				39+6	60	Negative	Negative	39.5	0	N	N/A
CASE	19	No	36+2	PE	37+5	11	38+0	13	Positive	Positive	35.2	13.4	N	N/A
CONTROL	20	No	36+4				40+2	26	Positive	Negative	≥40	0	N	N/A
CASE	21	No	37+6	PE	37+6	0	38+1	2	Negative	Positive	33.9	31.8	N	N/A
CONTROL	22	No	37+5				37+5	0	Positive	Negative	≥40	0	Positive	Negative
CASE	23	Severe	38+3	S-PE	38+3	0	38+4	1	Positive	Positive	15.1	14127744	Positive	Negative
CONTROL	24	Mild	38+3				38+3	0	Positive	Negative	≥40	0	N	N/A

CASE	25	No	38+5	PE	38+5	0	38+6	1	Positive	Negative	≥40	0	Negative	N/A
CONTROL	26	No	38+0				40+4	18	Positive	Negative	≥40	0	Negative	N/A
CASE	27	No	39+0	GHT	39+0	0	39+2	2	Positive	Negative	≥40	0	N/A	N/A
CONTROL	28	No	38+5				41+2	19	Negative	Negative	≥40	0	N/A	N/A

Table 2. Syn: Symptoms of SARS-COV-2 infection; GA: gestational age (week + days); HDP: hypertensive disorders of pregnancy; GHT: Gestational hypertension; PE: preeclampsia; S-PE: severe preeclampsia; DELIV-PE (Days):interval from diagnosis of COVID19 to HDP diagnosis, days; DELIV-SARS (Days): interval from diagnosis of COVID19 to delivery, days; CT: cycle threshold value RT-PCR; R: result; P: positive; N: negative; N/A: not available;

* RT-PCR was only performed if the latest negative RT-PCR test was more than 3 months ago.

the squares marked in blue color correspond to controls without HDP

Case 1

Placenta

Case 11